BioNTech (NSDQ:BNTX) announced today that it acquired Kite’s solid tumor neoantigen T cell receptor (TCR) platform and its facility in Maryland.
Mainz, Germany-based BioNTech said in a news release that the acquired clinical manufacturing facility in Gaithersburg, Md., will provide production capacity in support of U.S. clinical trials while complementing the company’s existing cell therapy manufacturing facility in Idar-Oberstein, Germany.
Kite’s Maryland facility will also support the development of BioNTech’s expanding pipeline of novel cell therapies, including cancer product candidates based on its CAR-T cell amplifying mRNA vaccine (CARVac) and Neostim platforms, as well as the newly acquired, individualized neoantigen TCR program.
The company said that all Kite employees at the Gaithersburg plant will be offered employment with BioNTech prior to the closing of the acquisition, while it also plans on further …